Abstract:We analyzed the translatome landscape in glioblastoma models, revealing that ribosome profiling detected significantly more translated genes than mass spectrometry, leading to detailed insights into protein translation mechanisms. We discovered novel peptides, translated lncRNAs and pseudogenes, along with radiation effects on histones and splicing factors, enriching glioblastoma research and opening avenues for future research that may improve cancer treatment outcomes. Glioblastoma (GB), the most common and aggressive brain tumor, demonstrates intrinsic resistance to current therapies, resulting in poor clinical outcomes. Cancer progression can be partially attributed to the deregulation of protein translation mechanisms that drive cancer cell growth. In this study, we present the translatome landscape of GB as a valuable data resource. Eight patient‐derived GB sphere cultures (GSCs) were analyzed using ribosome profiling and messenger RNA (mRNA) sequencing. We investigated inter‐cell‐line differences through differential expression analysis at both the translatome and transcriptome levels. Translational changes post‐radiotherapy were assessed at 30 and 60 min. The translation of non‐coding RNAs (ncRNAs) was validated using in‐house and public mass spectrometry (MS) data, whereas RNA expression was confirmed by quantitative PCR (qPCR). Our findings demonstrate that ribosome sequencing provides more detailed information than MS or transcriptional analyses. Transcriptional similarities among GSCs correlate with translational similarities, aligning with previously defined subtypes such as proneural and mesenchymal. Additionally, we identified a broad spectrum of open reading frame types in both coding and non‐coding mRNA regions, including long non‐coding RNAs (lncRNAs) and pseudogenes undergoing active translation. Translation of ncRNAs into peptides was independently confirmed by in‐house data and external MS data. We also observed that translational regulation of histones (downregulated) and splicing factors (upregulated) occurs in response to radiotherapy. These data offer new insights into genome‐wide protein synthesis, identifying translationally regulated genes and alternative translation initiation sites in GB under normal and radiotherapeutic conditions, providing a rich resource for GB research. Further functional validation of differentially expressed genes after radiotherapy is needed. Understanding translational control in GB can reveal mechanistic insights and identify currently unknown biomarkers, ultimately enhancing the diagnosis and treatment of this aggressive brain cancer.

Quantitative proteomic Isotope-Coded Protein Label (ICPL) analysis reveals alteration of several functional processes in the glioblastoma

Identification of Glioblastoma Phosphotyrosine-Containing Proteins with Two-Dimensional Western Blotting and Tandem Mass Spectrometry

Cnsc-08. Prognostic Biomarker Discovery Through Proteomic Analysis Of Glioblastoma Multiforme

Epco-58. Integrative Proteogenomic Analyses Reveal Insights Into Subtype-Specific Glioma Risk

Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells

BIOM-20. PROTEOMICS PROVIDES POTENTIAL THERAPEUTIC APPROACHES TO GLIOBLASTOMA TREATMENT: RESULTS FROM THE CLINICAL PROTEOMICS TUMOR ANALYSIS CONSORTIUM (CPTAC)

Proteomics Studies on Extracellular Vesicles Derived from Glioblastoma: Where Do We Stand?

Identification of T cell target antigens in glioblastoma stem-like cells using an integrated proteomics-based approach in patient specimens

Surfaceome Proteomic of Glioblastoma Revealed Potential Targets for Immunotherapy

Gene Expression Patterns Associated with Survival in Glioblastoma

A Quantitative Digital Analysis of Tissue Immune Components Reveals an Immunosuppressive and Anergic Immune Response with Relevant Prognostic Significance in Glioblastoma

Proteomic Analysis of Cerebrospinal Fluid: Toward the Identification of Biomarkers for Gliomas.

Proteometabolomics of initial and recurrent glioblastoma highlights an increased immune cell signature with altered lipid metabolism

Tmet-23. Mass Spectrometry-Based Metabolic Profiling And Imaging Of Astrocyte And Glioblastoma Invasive Margin Cells

Potential Glioblastoma Biomarkers Identified by Mass Spectroscopy and Itraq Labeling

Comparative proteogenomic characterization of glioblastoma

System biology approach to identify the novel biomarkers in glioblastoma multiforme tumors by using computational analysis

Identification of novel prognostic targets in glioblastoma using bioinformatics analysis

Identification of Core Genes and Screening of Potential Targets in Glioblastoma Multiforme by Integrated Bioinformatic Analysis

The translatome of glioblastoma

Unveiling the Molecular Mechanisms of Glioblastoma through an Integrated Network-Based Approach